Clinical Significance of Peripheral Blood Lymphocyte Subtypes and Cytokines in Patients with Hepatocellular Carcinoma Treated with TACE

References

• Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36.
   PubMed Web of Science ®Google Scholar
• Song B, Zhen S, Meng F. T cell inflammation profile after surgical resection may predict tumor recurrence in HBV-related hepatocellular carcinoma. Int Immunopharmacol. 2016;41:35–41.
   PubMed Web of Science ®Google Scholar
• Nandi M, Pal S, Ghosh S, et al. CD8CD28 T cells: key cytotoxic players impacting disease pathogenesis in chronic HBV infection. Clin Sci (Lond). 2019;133:1917–1934.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51:27–41.
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol. 2015;7:2080–2090.
   PubMed Web of Science ®Google Scholar
• Guo M, Yuan F, Qi F, et al. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8(+)T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med. 2020;18:306.
   PubMed Web of Science ®Google Scholar
• Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4:419–430.
   PubMed Web of Science ®Google Scholar
• Yao W, He JC, Yang Y, et al. The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a systematic review and meta-analysis. Sci Rep. 2017;7:7525.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Yuan BY, Chen GW, et al. Association between circulating lymphocyte populations and outcome after stereotactic body radiation therapy in patients with hepatocellular carcinoma. Front Oncol. 2019;9:896.
   PubMed Web of Science ®Google Scholar
• Langhans B, Nischalke HD, Kramer B, et al. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68:2055–2066.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109–118.
   PubMed Web of Science ®Google Scholar
• Sun B, Karin M. Inflammation and liver tumorigenesis. Front Med. 2013;7:242–254.
   PubMed Web of Science ®Google Scholar
• Budhu A, Forgues M, Ye Q-H, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99.
   PubMed Web of Science ®Google Scholar
• Liu HZ, Deng W, Li JL, et al. Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma. Oncotarget. 2016;7:77558–77564.
   PubMedGoogle Scholar
• Rochigneux P, Nault JC, Mallet F, et al. Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. Oncoimmunology. 2019;8:1615818.
   PubMed Web of Science ®Google Scholar
• Huang M, Wang X, Bin H. Effect of transcatheter arterial chemoembolization combined with argon-helium cryosurgery system on the changes of NK cells and T cell subsets in peripheral blood of hepatocellular carcinoma patients. Cell Biochem Biophys. 2015;73:787–792.
   PubMed Web of Science ®Google Scholar
• Loosen SH, Schulze-Hagen M, Leyh C, et al. IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies. Int J Mol Sci. 2018;19:1766.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54–74.
   PubMed Web of Science ®Google Scholar
• Wu Y, Fan W, Xue M, et al. Postintervention Interleukin-6 (IL-6) level, rather than the pretreatment or dynamic changes of IL-6, as an early practical marker of tumor response in hepatocellular carcinoma treated with transarterial chemoembolization. Oncologist. 2019;24:e1489–e95.
   PubMed Web of Science ®Google Scholar
• Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med. 2013;19:859–868.
   PubMed Web of Science ®Google Scholar
• Ren Z, Yue Y, Zhang Y, et al. Changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles. Front Immunol. 2021;12:624789.
   PubMed Web of Science ®Google Scholar
• Guo X, Du F, Liu Q, et al. Immunological effect of irreversible electroporation on hepatocellular carcinoma. BMC Cancer. 2021;21:443.
   PubMed Web of Science ®Google Scholar
• Qi F, Wang L, Huang P, Zhao Z, Yang B, Xia J. Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma. Oncol Lett. 2020;19:1175–1186.
   PubMed Web of Science ®Google Scholar
• Jekarl DW, Lee S, Kwon JH, et al. Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma. PLoS One. 2019;14:e0224318.
   PubMed Web of Science ®Google Scholar
• Shao Q, O’Flanagan S, Lam T, et al. Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. Int J Hyperthermia. 2019;36:130–138.
   PubMed Web of Science ®Google Scholar
• Ayaru L, Pereira SP, Alisa A, et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. 2007;178:1914–1922.
   PubMed Web of Science ®Google Scholar
• Liao Y, Wang B, Huang ZL, et al. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study. PLoS One. 2013;8:e60444.
   PubMed Web of Science ®Google Scholar
• Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68:916–927.
   PubMed Web of Science ®Google Scholar
• Agdashian D, ElGindi M, Xie C, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68:599–608.
   PubMed Web of Science ®Google Scholar
• Rice SJ, Liu X, Zhang J, Jia B, Zheng H, Belani CP. Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling. Lung Cancer. 2019;131:58–61.
   PubMed Web of Science ®Google Scholar
• Zhao S, Wu D, Wu P, Wang Z, Serum HJ. IL-10 predicts worse outcome in cancer patients: a meta-analysis. PLoS One. 2015;10:e0139598.
   PubMed Web of Science ®Google Scholar
• El-Emshaty HM, Nasif WA, Mohamed IE. Serum Cytokine of IL-10 and IL-12 in chronic liver disease: the immune and inflammatory response. Dis Markers. 2015;2015:707254.
   PubMed Web of Science ®Google Scholar
• Wilke CM, Wei S, Wang L, Kryczek I, Kao J, Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-gamma. Cancer Immunol Immunother. 2011;60:1529–1541.
   PubMed Web of Science ®Google Scholar
• Lee IC, Huang Y-H, Chau G-Y, et al. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer. 2013;133:2895–2902.
   PubMed Web of Science ®Google Scholar
• Lee HL, Jang JW, Lee SW, et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep. 2019;9:3260.
   PubMed Web of Science ®Google Scholar
• Liu X, Li M, Wang X, et al. PD-1 TIGIT CD8 T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68:2041–2054.
   PubMed Web of Science ®Google Scholar
• Qian J, Wang C, Wang B, et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation. 2018;15:290.
   PubMed Web of Science ®Google Scholar
• Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18:121–126.
   PubMed Web of Science ®Google Scholar
• Gai X, Zhou P, Xu M, Liu Z, Zheng X, Liu Q. Hyperactivation of IL-6/STAT3 pathway leaded to the poor prognosis of post-TACE HCCs by HIF-1α/SNAI1 axis-induced epithelial to mesenchymal transition. J Cancer. 2020;11:570–582.
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Nakamoto Y, Arai K, et al. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J Cancer. 2010;126:2164–2174.
   PubMed Web of Science ®Google Scholar
• Singh P, Toom S, Avula A, Kumar V, Rahma OE. The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2020;7:11–17.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Jang JW, Oh BS, et al. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. Cytokine. 2013;64:516–522.
   PubMed Web of Science ®Google Scholar
• Zhao J, Li Q, Muktiali M, et al. Effect of microwave ablation treatment of hepatic malignancies on serum cytokine levels. BMC Cancer. 2020;20:812.
   PubMed Web of Science ®Google Scholar
• Ma B, Liu X, Yu Z. The effect of high intensity focused ultrasound on the treatment of liver cancer and patients’ immunity. Cancer Biomark. 2019;24:85–90.
   PubMed Web of Science ®Google Scholar